Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma 3Neoplasms 2Brain Neoplasms 2Spinal Cord Neoplasms 1Neoplasm Metastasis 1Central Nervous System Neoplasms 1

Interventions

Rituximab 57Cyclophosphamide 56fludarabine 37fludarabine phosphate 31Filgrastim 27Etoposide 22Bortezomib 20Melphalan 19Gemcitabine 19Cytarabine 17Bendamustine Hydrochloride 17Peripheral Blood Stem Cell Transplantation 16Vincristine 15pembrolizumab 14aldesleukin 13Prednisone 13Doxorubicin 12Dexamethasone 12Busulfan 12Whole-Body Irradiation 11Vorinostat 11Tacrolimus 11Sirolimus 11sargramostim 10obinutuzumab 10Lenalidomide 10romidepsin 9Radiotherapy 9Rifampin 8Paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma × RRx-001 × Clear all
NCT01359982 2024-11-01

DINAMIC

EpicentRx, Inc.

Phase 1 Completed
26 enrolled 11 charts
Lymphoid

Lymphoma, Neoplasms

NCT02518958 2019-11-18

PRIMETIME

EpicentRx, Inc.

Phase 1 Completed
12 enrolled
Lymphoid

Lymphoma

NCT02096341 2016-01-21

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

EpicentRx, Inc.

Phase 1 Terminated
2 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡